{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 439545413
| IUPAC_name = 5-phenyl-3,4,6,7,8,9-hexahydro-[1]benzothiolo[2,3-''e''][1,4]diazepin-2-one
| image = Bentazepam.svg
| width = 150

<!--Clinical data-->
| tradename = Tiadipona <small>([[Spain|ES]])</small>
| Drugs.com = {{drugs.com|international|bentazepam}}
| pregnancy_category = 
| legal_US = Schedule IV
| routes_of_administration = Oral ([[Tablet (pharmacy)|tablets]])

<!--Pharmacokinetic data-->
| bioavailability = 
| metabolism = [[Liver|Hepatic]]
| elimination_half-life = 2–4 hours
| excretion = [[Kidney|Renal]]

<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 29462-18-8
| ATC_prefix = N05
| ATC_suffix = BA24
| ATC_supplemental = 
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 1521495
| PubChem = 34592
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = 
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 11248641
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 66JKK43S1Z
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D03083

<!--Chemical data-->
| C=17 | H=16 | N=2 | O=1 | S=1
| molecular_weight = 296.387 g/mol
| smiles = O=C1CN=C(C2=CC=CC=C2)C3=C(N1)SC4=C3CCCC4
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C17H16N2OS/c20-14-10-18-16(11-6-2-1-3-7-11)15-12-8-4-5-9-13(12)21-17(15)19-14/h1-3,6-7H,4-5,8-10H2,(H,19,20)
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = AIZFEOPQVZBNGH-UHFFFAOYSA-N
}}

'''Bentazepam'''<ref>DE Patent 2005276</ref> (also known as '''Thiadipone''', '''Tiadipona''') is a [[thienodiazepine]] which is a [[benzodiazepine]] analog.<ref name=potana/>

It possesses [[anxiolytic]], [[anticonvulsant]], [[sedative]] and [[skeletal muscle relaxant]] properties.
Peak plasma rates are achieved in around 2,5 hours after oral administration.<ref>{{cite journal |pmid=3429066 |year=1987 |last1=Mariño |first1=EL |last2=Fernandez Lastra |last3=Gonzalez Lopez |last4=Dominguez-Gil |last5=Garcia Santalla |last6=Vorca |last7=Izquierdo |last8=Ledesma-Jimeno |title=Parametrization by non-linear regression and bayesian estimation of bentazepam in a multiple dosage regimen in humans |volume=25 |issue=11 |pages=627–32 |journal=International journal of clinical pharmacology, therapy, and toxicology |first2=C |first3=F |first4=A |first5=JL |first6=G |first7=JA |first8=A }}</ref> The elimination half-life is between approximately 2–4 hours.<ref name=potana>{{cite journal |pmid=2877954 |year=1986 |last1=Gonzalez López |first1=F |last2=Mariño |last3=Dominguez-Gil |title=Pharmacokinetics of tiadipone: a new anxiolytic |volume=24 |issue=9 |pages=482–4 |journal=International journal of clinical pharmacology, therapy, and toxicology |first2=EL |first3=A }}</ref><ref>{{cite journal |pmid=1800395 |year=1991 |last1=Colino |first1=CI |last2=Lastra |last3=López |last4=Ledesma |last5=Mariño |title=Open-loop feedback control of serum bentazepam concentrations and Bayesian estimation in multiple dosage regimens in patients. |volume=29 |issue=11 |pages=457–62 |journal=International journal of clinical pharmacology, therapy, and toxicology |first2=CF |first3=FG |first4=A |first5=EL }}</ref> Bentazepam is effective as an anxiolytic.

A severe [[benzodiazepine overdose]] with bentazepam may result in coma and respiratory failure.<ref>{{cite journal |pmid=2565591 |year=1989 |last1=Rivas López |first1=FA |last2=López Soriano |last3=Mendoza Cerezo |last4=Jiménez Ferré |last5=Azurmendi Rodríguez |last6=De La Rubia Nieto |title=Mixed benzodiazepine poisoning and reversal with flumazenil (Ro 15-1788) |volume=36 |issue=1 |pages=48–50 |journal=Revista espanola de anestesiologia y reanimacion |first2=F |first3=A |first4=J |first5=JI }}</ref> Adverse effects include dry mouth, [[somnolence]], [[asthenia]], [[dyspepsia]], [[constipation]], [[nausea]]<ref>{{cite journal |pmid=1983365 |year=1990 |last1=Honorato |first1=J |last2=Rubio |last3=Tristán |last4=Otero |last5=Garrido |title=A pharmacovigilance study with bentazepam in a sample of 1046 psychiatric outpatients |volume=34 |issue=2 |pages=80–8 |journal=Revista de medicina de la Universidad de Navarra |first2=A |first3=C |first4=FJ |first5=J }}</ref> and drug-induced [[lymphocytic colitis]] has been associated with bentazepam.<ref>{{cite journal |pmid=12591052 |year=2003 |last1=Fernández-Bañares |first1=F |last2=Salas |last3=Esteve |last4=Espinós |last5=Forné |last6=Viver |title=Collagenous and lymphocytic colitis. evaluation of clinical and histological features, response to treatment, and long-term follow-up. |volume=98 |issue=2 |pages=340–7 |doi=10.1111/j.1572-0241.2003.07225.x |journal=The American journal of gastroenterology |first2=A |first3=M |first4=J |first5=M |first6=JM }}</ref><ref>{{cite journal |pmid=9451703 |year=1997 |last1=De-La-Serna |first1=C |last2=Gil-Grande |last3=Sanromán |last4=Gonzalez |last5=Ruiz-Del-Arbol |last6=Garcia Plaza |title=Bentazepam-induced hepatic bridging necrosis. |volume=25 |issue=4 |pages=710–1 |journal=Journal of Clinical Gastroenterology |doi=10.1097/00004836-199712000-00042 |first2=LA |first3=AL |first4=M |first5=L |first6=A }}</ref> Severe liver damage and hepatitis has also been associated with bentazepam.<ref>{{cite journal |pmid=17133470 |year=2006 |last1=Andrade |first1=RJ |last2=Lucena |last3=Kaplowitz |last4=García-Muņoz |last5=Borraz |last6=Pachkoria |last7=García-Cortés |last8=Fernández |last9=Pelaez |title=Outcome of acute idiosyncratic drug-induced liver injury: Long-term follow-up in a hepatotoxicity registry |volume=44 |issue=6 |pages=1581–8 |doi=10.1002/hep.21424 |journal=Hepatology |first2=MI |first3=N |first4=B |first5=Y |first6=K |first7=M |first8=MC |first9=G |last10=Rodrigo |first10=Luis |last11=Durán |first11=José A. |last12=Costa |first12=Joan |last13=Planas |first13=Ramón |last14=Barriocanal |first14=Anabel |last15=Guarner |first15=Carlos |last16=Romero-Gomez |first16=Manuel |last17=Muņoz-Yagüe |first17=Teresa |last18=Salmerón |first18=Javier |last19=Hidalgo |first19=Ramón |display-authors=8 }}</ref><ref>{{cite journal |pmid= |url=http://www.elsevier.es/revistas/ctl_servlet?_f=7064&ip=90.221.211.72&articuloid=13047309&revistaid=2 |language=Spanish |journal=Medicina Clinica |title=Utilidad clinica del acetato de megestrol para la ganancia de peso en los enfermos con neoplasia y caquexia |volume=120 |issue=17 |pages=678 |year=2003 |doi= 10.1157/13047309 |last1= Tuca |first1= Albert }}</ref><ref>{{cite journal |pmid=7908109 |year=1994 |last1=Andrade |first1=RJ |last2=Lucena |last3=Alcantara |last4=Fraile |title=Bentazepam-associated chronic liver disease. |volume=343 |issue=8901 |pages=860 |journal=Lancet |doi=10.1016/S0140-6736(94)92065-6 |first2=MI |first3=R |first4=JM }}</ref> Whilst liver failure from bentazepam is considered to be rare, liver function monitoring has been recommended for all patients taking bentazepam.<ref>{{cite journal |pmid=10961721 |year=2000 |last1=Andrade |first1=RJ |last2=Lucena |last3=Aguilar |last4=Lazo |last5=Camargo |last6=Moreno |last7=García-Escaño |last8=Marquez |last9=Alcántara |title=Chronic liver injury related to use of bentazepam: an unusual instance of benzodiazepine hepatotoxicity |volume=45 |issue=7 |pages=1400–4 |journal=Digestive diseases and sciences |doi=10.1023/A:1005520523502 |first2=MI |first3=J |first4=MD |first5=R |first6=P |first7=MD |first8=A |first9=R |last10=Alcáin |first10=G. |display-authors=8 }}</ref>

==See also==
* [[List of benzodiazepines]]

==References==
{{Reflist|2}}

{{Benzodiazepines}}
{{GABAAR PAMs}}

[[Category:GABAA receptor positive allosteric modulators]]
[[Category:Hypnotics]]
[[Category:Lactams]]
[[Category:Thienodiazepines]]


{{sedative-stub}}